Jill Stein


Nab-Paclitaxel Boosts Survival in Pancreatic Cancer

December 4th 2013

The addition of albumin-bound paclitaxel (nab-paclitaxel; Abraxane) to standard treatment with gemcitabine significantly lengthens survival in patients with metastatic pancreatic cancer, researchers report.

Stem Cell Transplantation May Impair Sexual Health

December 3rd 2013

Both men and women report a significant decline in sexual satisfaction after hematopoietic cell transplantation that is sustained at 3-year follow-up.

G-CSF Prophylaxis Recommended Throughout Chemotherapy in Breast Cancer Patients at Risk for Febrile Neutropenia

November 22nd 2013

A Dutch team is recommending the continued use of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis throughout all chemotherapy cycles in women with early breast cancer who are at high risk of febrile neutropenia (FN).

Breast Cancer Patients Prefer Subcutaneous Trastuzumab

November 12th 2013

Women with HER2-positive early breast cancer favor subcutaneous over intravenous (IV) administration of trastuzumab (Herceptin).

ALK-Positive Criteria for Determining Crizotinib Use May Fall Short

November 4th 2013

The criteria that are presently used to determine whether patients with non-small cell lung cancer may be suitable for treatment with the ALK inhibitor crizotinib may overlook some patients who may benefit from the drug.

Colonoscopy Screening at 10-Year Intervals May Prevent 40% of Colorectal Cancers

October 30th 2013

Forty percent of cases of colorectal cancer may be prevented if patients at average risk for the disease undergo a screening colonoscopy every 10 years

Some Prostate Cancers Unaffected, Others Prevented With 5ARIs

July 29th 2013

Investigators say they have found no association between the use of 5-alpha-reductase inhibitors (5ARIs) and the risk of developing high-grade or lethal prostate cancer.

Low-Dose Radioiodine Ablation Is Effective Treatment for Thyroid Cancer

December 11th 2012

Low-dose radioiodine ablation with thyrotropin alfa is as effective as high-dose radioiodine ablation in patients with differentiated thyroid cancer and is safer.

Adjunctive Ketamine Does Not Relieve Cancer Pain

December 5th 2012

Subcutaneous ketamine administered in conjunction with opioids and conventional adjuvant therapy does not lessen chronic uncontrolled cancer pain, according to the results of a phase III study. The regimen also produces a significant spike in toxicity.

Pain in Oncology Outpatients With Solid Tumors Remains Undertreated

December 3rd 2012

Pain is as prevalent in ambulatory oncology patients with common solid tumors as it was nearly two decades ago despite the dramatic increase in opioid prescriptions.

Meningioma May Be Tied to Dental X-Rays

November 29th 2012

New data suggest that dental x-rays obtained frequently at a young age may boost the risk of intracranial meningioma.

Addition of Motesanib to Chemotherapy Offers No Benefit for Patients With Non-Small Cell Lung Cancer

November 27th 2012

Motesanib combined with carboplatin/paclitaxel does not significantly improve OS versus carboplatin/ paclitaxel alone in patients with advanced nonsquamous non–small cell lung cancer, according to the results of the phase III MONET1 study.

Patient and Physician Decision Practices Influence Chemotherapy Use in Older Patients With Breast Cancer

November 21st 2012

Older women with breast cancer who prefer less input from their physician when deciding on treatment are less likely to receive chemotherapy than women who prefer to rely on their physician to a greater degree, a recent study has found.

L-carnitine Not Effective for Cancer Fatigue

November 8th 2012

Patients receiving a daily regimen of L-carnitine did not experience improved fatigue versus placebo on the widely validated Brief Fatigue Inventory.

Lapatinib Plus Trastuzumab Bests Lapatinib Monotherapy in HER2-Positive Metastatic Breast Cancer

November 7th 2012

Investigators have documented a significant 4.5-month median overall survival advantage with lapatinib combined with trastuzumab in women with heavily pretreated HER2-positive metastatic breast cancer.

Beta-Carotene Antioxidant Use Is Safe During Radiotherapy for Prostate Cancer

November 6th 2012

Men who take the dietary antioxidant beta-carotene while they are undergoing radiation therapy for prostate cancer do not have an increased risk of prostate cancer death or metastases.

No Survival Benefit Found When Adding Bevacizumab to Gemcitabine/Cisplatin in Malignant Mesothelioma

October 31st 2012

The addition of bevacizumab to gemcitabine/cisplatin does not significantly improve progression-free survival or overall survival in patients with previously untreated, unresectable malignant mesothelioma.

Elevated Cholesterol Linked to Aggressive Prostate Cancer

October 29th 2012

Men with increased cholesterol levels may have an elevated risk of developing high-grade prostate cancer.

Extending Adjuvant Chemotherapy Offers No Additional Benefit in Low-Risk Primary Breast Cancer

October 29th 2012

Six cycles of doxorubicin and cyclophosphamide or single-agent paclitaxel do not lead to a superior outcome versus four cycles as adjuvant chemotherapy in women with resected primary breast cancer.

Laxative-Free CTC Examined as Potential Alternative to Standard Colonoscopy

October 25th 2012

Computer-aided computed tomographic colonography that does not require a laxative preparation nearly rivals conventional optical colonoscopy for identifying asymptomatic adults with adenomas.